Related Experiment Videos
[Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase]
M Wlazłowski1, W Celińska, L Maciejka-Kapuścińska
1I Kliniki Chorób Dzieci w Gdańsku.
Insights
L-asparaginase treatment for childhood acute lymphoblastic leukemia can cause severe adverse reactions like pancreatitis and hyperglycemia. Monitoring is crucial as 8% developed pancreatitis and 10% had hyperglycemia, sometimes requiring treatment changes.
Area of Science:
- Biochemistry
- Pediatric Oncology
- Enzymology
Background:
- L-asparaginase is a critical enzyme in treating childhood acute lymphoblastic leukemia (ALL).
- It is derived from bacterial sources like E. coli and Erwinia chrysanthemi.
- Adverse reactions are common, with pancreatitis being a significant concern.
Observation:
- A 2-year follow-up study monitored children undergoing L-asparaginase therapy for ALL.
- Hyperglycemia and glycosuria were observed in 10% of the pediatric patients.
- Acute pancreatitis occurred in 8% of the children treated with L-asparaginase.
Findings:
- The study identified hyperglycemia and glycosuria as notable side effects of L-asparaginase treatment.
- A significant percentage of children (8%) experienced acute pancreatitis.
- These adverse events sometimes necessitated the discontinuation or modification of L-asparaginase therapy.
Implications:
- Findings highlight the need for vigilant monitoring of metabolic and pancreatic function in children receiving L-asparaginase.
- The occurrence of hyperglycemia and pancreatitis suggests potential mechanisms of L-asparaginase toxicity.
- Identifying and managing these adverse reactions is essential for optimizing treatment outcomes in pediatric ALL.
Abstract:
The treatment of the acute lymphoblastic leukemia in childhood includes frequent administration of L-asparaginase by intravenous route. L-asparaginase is an enzyme produced by E. coli and Erwinia chrysanthemi strains. Adverse reactions produced by L-asparaginase are numerous, and pancreatitis is being the most severe. Children with the acute lymphoblastic leukemia were followed up for 2 years. Hyperglycaemia and glycosuria were noted in 10% of them resulting in L-asparaginase cessation or replacement by less toxic agents. The acute pancreatitis was produced in 8% of the patients, and was treated typically.